Last updated: July 28, 2026
OSI Pharmaceuticals v. Apotex (1:15-cv-00772): Litigation Summary, Patent-List Implications, and Generic-Risk Assessment
Executive summary: OSI Pharmaceuticals, LLC is pursuing patent enforcement in case no. 1:15-cv-00772 against Apotex Inc. arising from ANDA/generic entry risk for an OSI-branded oncology product. The docket posture (complaint filed in 2015; active case administration thereafter) indicates a standard Hatch-Waxman dispute path: infringement allegations tied to one or more Orange Book listed patents, with the litigation designed to delay FDA approval and launch. Without the case’s substantive filing set, claim-to-patent mapping, and final orders, a complete infringement/validity analysis by asserted patent cannot be produced.
What patents did OSI Pharmaceuticals assert against Apotex in 1:15-cv-00772?
Answer (what can be stated precisely): No asserted-patent list, Orange Book patent numbers, or claim charts are provided in the available input. Without the complaint (or amended complaint), the asserted patent identities, claims, and theories (infringement, induced infringement, willful infringement) cannot be enumerated.
Which Orange Book patents typically drive OSI v. Apotex cases?
For OSI oncology portfolio disputes, the asserted set commonly spans:
- Drug substance or crystalline form patents (form/solvate/polymorph control)
- Drug product formulation patents (composition, excipients, coating, dissolution)
- Method-of-use patents (dosage regimen, patient selection, combination regimens)
- Manufacturing/process patents (specific steps or yield/impurity controls)
But the specific asserted patent set for 1:15-cv-00772 cannot be stated from the current input.
What is the procedural history of OSI Pharmaceuticals, LLC v. Apotex Inc. (1:15-cv-00772)?
Answer (what can be stated precisely): The case is identified as 1:15-cv-00772 and includes OSI Pharmaceuticals, LLC as plaintiff and Apotex Inc. as defendant. The litigation began in 2015 based on the docket number year.
Hatch-Waxman procedural milestones to check in this docket
A complete analysis normally tracks:
- Complaint and alleged infringement tied to specific Orange Book patents
- ANDA Paragraph IV framework and any counterclaims for invalidity/non-infringement
- Markman (claim construction) schedule and resulting constructions
- Summary judgment outcomes on eligibility, indefiniteness, obviousness, written description, enablement, or infringement
- Trial verdict or stipulated dismissal/consent judgment
- Appellate posture if any
Those milestone outcomes and dates are not present in the provided input, so they cannot be reported.
What did OSI Pharmaceuticals claim Apotex’s ANDA would infringe?
Answer (what can be stated precisely): The input does not include the underlying product identity (drug name), the ANDA number, or the asserted Orange Book patents. Therefore, infringement scope and claim elements cannot be mapped.
How infringement is typically argued in OSI-led Hatch-Waxman cases
Common infringement theories include:
- Direct infringement based on ANDA label-directed use and composition
- Infringement by combination or regimen if the proposed label matches method claims
- Alleged induced infringement if the label instructs the infringing regimen
- Label carve-outs and how courts treat them
No label text, ANDA proposed prescribing information, or claim-element mapping is available here.
What defenses did Apotex raise in OSI Pharmaceuticals v. Apotex (1:15-cv-00772)?
Answer (what can be stated precisely): The provided input does not include Apotex’s counterclaims or motion outcomes. Standard Hatch-Waxman defenses include non-infringement and invalidity under 35 USC §§ 101, 102, 103, and 112, but the case-specific defense slate cannot be asserted without the docket filings.
Which court handled OSI v. Apotex, and what does the venue imply for strategy?
Answer (what can be stated precisely): The docket number indicates a federal case, but the district/court division and judge are not included in the input. Venue and judge-level tendencies can materially affect:
- Claim construction leanings
- Speed-to-markman and summary judgment timing
- Damages framing and standard for willfulness
Without the judge and district, this analysis cannot be completed.
When does OSI’s patent estate lose exclusivity after 1:15-cv-00772?
Answer (what can be stated precisely): Exclusivity and expiration timelines depend on:
- The specific Orange Book listed patents asserted in the case
- Their priority/filing dates
- Any PTA/PTE
- Any pediatric exclusivity or regulatory exclusivity overlays
- Whether the litigation ended in settlement (and what trigger dates were agreed)
Because no asserted patents or product are identified, exclusivity timelines cannot be computed.
Did OSI win, settle, or dismiss in case 1:15-cv-00772?
Answer (what can be stated precisely): No final judgment, settlement agreement summary, dismissal order, or consent decree is provided in the input. As a result:
- Outcome cannot be reported
- Trigger terms cannot be summarized
- Launch timing consequences cannot be tied to the court record
How do settlement terms typically affect Apotex launch timing in OSI oncology disputes?
Answer (what can be stated precisely): The specific settlement terms for 1:15-cv-00772 are not available in the input, so no numeric launch date, stipulated design-around, or agreed entry mechanism can be given.
Settlement levers usually negotiated in Hatch-Waxman
Common provisions include:
- Agreed launch dates tied to patent expiration
- Carve-outs for non-infringement of certain claims
- Label restrictions to avoid method-of-use infringement
- Reversion clauses if the patent is held invalid
- Cross-licenses or covenant-not-to-sue scopes
No such terms are included here.
What is the Orange Book status of the OSI product involved in 1:15-cv-00772?
Answer (what can be stated precisely): The input provides no drug identity and no Orange Book listing. Orange Book status cannot be provided.
How to read the Orange Book in this context
A complete Orange Book analysis requires:
- The NDA/ANDA reference listed drug
- Listed patents (drug substance, drug product, and method-of-use)
- Patent expiration and any exclusivity extensions
- Whether patents are subject to litigation stays
No Orange Book identifiers (NDA number, RLD name) are present.
What generic entry risks exist for Apotex after OSI v. Apotex (1:15-cv-00772)?
Answer (what can be stated precisely): Risk depends on:
- The litigation outcome (infringement, invalidity, settlement)
- Remaining unasserted patents in the Orange Book
- Whether Apotex can design around formulation or method claims
- Whether FDA approval is stayed until a court event
Because outcome and patent list are not provided, the risk level cannot be quantified.
How strong is OSI’s patent estate in this dispute?
Answer (what can be stated precisely): Patent strength must be judged against:
- Asserted claims and prior art landscape
- Claim construction outcomes
- Final invalidity conclusions and their evidentiary basis
- Written description and enablement record
- Anticipation/obviousness support
No asserted patents or claim outcomes are present.
What manufacturing or formulation design-arounds could matter for Apotex?
Answer (what can be stated precisely): Design-around feasibility is patent-specific (crystal form, excipient system, dissolution profile, particle size, manufacturing step). Without the formulation/polymorph/process patents asserted, no design-around route can be described.
Case comparison: How OSI v. Apotex typically differs from other oncology Hatch-Waxman disputes
Answer (what can be stated precisely): OSI-led disputes often follow a similar pattern (Orange Book patents, ANDA Paragraph IV framework, method-of-use exposure). But case-specific differences (composition versus method, combination label relevance, polymorph/form, procedural posture) cannot be stated without the case filings.
Key Takeaways
- Case identification is confirmed as OSI Pharmaceuticals, LLC v. Apotex Inc., 1:15-cv-00772.
- A complete litigation summary cannot be produced from the provided input because it lacks the elements needed for a patent-accurate analysis: asserted patent list, product identity, ANDA number, court/judge, procedural milestones, and final outcome.
- Business actions that rely on this case (launch-date forecasting, freedom-to-operate mapping, Paragraph IV risk assessment, settlement economics) cannot be quantified without the underlying docket substance.
FAQs
- What is the asserted-patent list in OSI Pharmaceuticals, LLC v. Apotex Inc. (1:15-cv-00772)?
- Which Orange Book patents are tied to the ANDA dispute underlying case 1:15-cv-00772?
- Did OSI Pharmaceuticals obtain an injunction or a stay in 1:15-cv-00772?
- What settlement terms (launch date, label carve-outs, covenants) resolved 1:15-cv-00772?
- What is the current status of Apotex’s ANDA for the product involved in OSI v. Apotex 1:15-cv-00772?
References
- No citable sources were provided in the input.
